Inclusion Criteria:

• Male participants aged 30 to 75 years.
• Able and willing to provide written informed consent.
• Generally healthy, as determined by medical history and screening assessments.
• Willing and able to comply with all study procedures, including blood collection, daily study-product intake, and required study visits.
• Willing to consume the assigned cocoa flavanol supplement or low-flavanol control product once daily for the duration of the study.
• Willing to provide peripheral blood samples at baseline and at the end of the intervention.
• Willing to maintain generally stable dietary, exercise, sleep, medication, and supplement habits during the study.
• Willing to refrain from initiating new supplements, restrictive diets, fasting regimens, or major exercise programs during the study.
• Not currently taking medications or supplements known to substantially affect vascular function, nitric oxide pathways, inflammation, oxidative stress, or coagulation, unless approved by the investigator.

Exclusion Criteria:

• Female biological sex.
• Younger than 30 years or older than 75 years.
• Known cardiovascular, metabolic, renal, hepatic, inflammatory, or autoimmune disease, including coronary artery disease, diabetes mellitus, chronic kidney disease, chronic liver disease, rheumatoid arthritis, or another clinically significant inflammatory disorder.
• Hypertension requiring prescription medication.
• Active infection, acute illness, or other clinically significant medical condition at screening or baseline.
• Current use of medications or supplements that may substantially affect vascular function, inflammatory biomarkers, nitric oxide pathways, oxidative stress, or coagulation, including chronic nonsteroidal anti-inflammatory drugs, systemic corticosteroids, anticoagulants, antiplatelet drugs, prescription immunomodulatory agents, phosphodiesterase-5 inhibitors, or high-dose antioxidant supplements, unless approved by the investigator.
• Known allergy, hypersensitivity, or intolerance to cocoa, chocolate, cocoa flavanols, or any ingredient in either study product.
• Gastrointestinal disease or condition that may interfere with digestion or absorption of the study product, including celiac disease, inflammatory bowel disease, active gastritis, or a clinically significant malabsorption disorder.
• Current smoking or vaping of nicotine or cannabis products.
• Major psychiatric illness, cognitive impairment, or another condition that may interfere with informed consent, adherence, or completion of study procedures.
• Alcohol or drug abuse within the previous 12 months that, in the investigator's judgment, may affect participant safety or study adherence.
• Participation in another interventional clinical study within 30 days before screening.
• Plans to begin a new medication, supplement, restrictive diet, fasting regimen, or major exercise program during the study period.
• Any condition or circumstance that, in the investigator's judgment, would increase participant risk, interfere with study procedures, compromise adherence, or affect interpretation of the study results.